专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140179670A1 URACIL DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES 有权
标题翻译：尿嘧啶衍生物及其用于医疗用途
公开(公告)号：US20140179670A1
公开(公告)日：2014-06-26
申请号：US14236571
申请日：2012-07-31
申请人： Tomoya Shiro , Masanori Tobe , Katsumi Kubota , Yosuke Takanashi , Tomoaki Nakamura , Toshihiko Sone
发明人： Tomoya Shiro , Masanori Tobe , Katsumi Kubota , Yosuke Takanashi , Tomoaki Nakamura , Toshihiko Sone
IPC分类号： C07D403/04 , C07D401/04 , C07D417/14 , C07D403/14 , C07D413/14 , C07D401/14 , C07D405/14
CPC分类号： C07D403/04 , C07D401/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07F7/1804
摘要： The present invention provides: an uracil derivative represented by general formula (I) or a physiologically acceptable salt thereof (in the formula, R1 represents a hydrogen atom, a C1-10 alkyl group, a C2-6 alkene group or a 3- to 6-membered saturated or 4- to 6-membered unsaturated aliphatic ring group which may contain 1 to 2 hetero atoms independently selected from the group consisting of N, O and S; R2 represents a hydrogen atom, a halogen atom, a cyano group, —NRcRd, —N═CHN(CH3)2, or an C1-3 alkyl group; Ar1 and Ar2 independently represent a 5- to 6-membered aromatic ring group which may contain 1 to 3 hetero atoms independently selected from the group consisting of N, O and S; and L represents a 6-membered aromatic ring group which may contain 1 to 4 nitrogen atoms, a pyrazole group, a triazole group, or an imidazole group); and a therapeutic agent or prophylactic agent for various inflammatory diseases associated with elastase, comprises the compound or the like as an active ingredient.
摘要翻译：本发明提供：由通式（I）表示的尿嘧啶衍生物或其生理学上可接受的盐（式中，R1表示氢原子，C1-10烷基，C2-6烯基或3-至可以含有1〜2个独立地选自N，O和S的杂原子的6元饱和或4〜6元不饱和脂肪族环基; R2表示氢原子，卤素原子，氰基， -NR c R d，-N = CHN（CH 3）2或C 1-3烷基; Ar 1和Ar 2独立地表示可以含有1-3个独立地选自以下的杂原子的5至6元芳族环基团： N，O和S; L表示可含有1至4个氮原子的6元芳族环基，吡唑基，三唑基或咪唑基）。和用于与弹性蛋白酶相关的各种炎性疾病的治疗剂或预防剂包含作为活性成分的化合物等。

2. 发明授权

US09040516B2 Uracil derivative and use thereof for medical purposes 有权
标题翻译：尿嘧啶衍生物及其用途用于医疗用途
公开(公告)号：US09040516B2
公开(公告)日：2015-05-26
申请号：US14236571
申请日：2012-07-31
申请人： Tomoya Shiro , Masanori Tobe , Katsumi Kubota , Yosuke Takanashi , Tomoaki Nakamura , Toshihiko Sone
发明人： Tomoya Shiro , Masanori Tobe , Katsumi Kubota , Yosuke Takanashi , Tomoaki Nakamura , Toshihiko Sone
IPC分类号： A61K31/505 , A61K31/4015 , A61K31/497 , A61K31/535 , A61K31/54 , C07D401/04 , C07D403/14 , C07D413/14 , C07D417/14 , C07D403/04 , C07D401/14 , C07D405/14 , C07D409/14
CPC分类号： C07D403/04 , C07D401/04 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07F7/1804
摘要： The present invention provides: an uracil derivative represented by general formula (I) or a physiologically acceptable salt thereof (in the formula, R1 represents a hydrogen atom, a C1-10 alkyl group, a C2-6 alkene group or a 3- to 6-membered saturated or 4- to 6-membered unsaturated aliphatic ring group which may contain 1 to 2 hetero atoms independently selected from the group consisting of N, O and S; R2 represents a hydrogen atom, a halogen atom, a cyano group, —NRcRd, —N═CHN(CH3)2, or an C1-3 alkyl group; Ar1 and Ar2 independently represent a 5- to 6-membered aromatic ring group which may contain 1 to 3 hetero atoms independently selected from the group consisting of N, O and S; and L represents a 6-membered aromatic ring group which may contain 1 to 4 nitrogen atoms, a pyrazole group, a triazole group, or an imidazole group); and a therapeutic agent or prophylactic agent for various inflammatory diseases associated with elastase, comprises the compound or the like as an active ingredient.
摘要翻译：本发明提供：由通式（I）表示的尿嘧啶衍生物或其生理学上可接受的盐（式中，R1表示氢原子，C1-10烷基，C2-6烯基或3-至可以含有1〜2个独立地选自N，O和S的杂原子的6元饱和或4〜6元不饱和脂肪族环基; R2表示氢原子，卤素原子，氰基， -NR c R d，-N = CHN（CH 3）2或C 1-3烷基; Ar 1和Ar 2独立地表示可以含有1-3个独立地选自以下的杂原子的5至6元芳族环基团： N，O和S; L表示可含有1至4个氮原子的6元芳族环基，吡唑基，三唑基或咪唑基）。和用于与弹性蛋白酶相关的各种炎性疾病的治疗剂或预防剂包含作为活性成分的化合物等。

3. 发明授权

US07754728B2 Adenine compound and use thereof 失效
标题翻译：腺嘌呤化合物及其用途
公开(公告)号：US07754728B2
公开(公告)日：2010-07-13
申请号：US10528343
申请日：2003-09-26
申请人： Yoshiaki Isobe , Haruo Takaku , Haruhisa Ogita , Masanori Tobe , Ayumu Kurimoto , Tetsuhiro Ogino , Hitoshi Fujita
发明人： Yoshiaki Isobe , Haruo Takaku , Haruhisa Ogita , Masanori Tobe , Ayumu Kurimoto , Tetsuhiro Ogino , Hitoshi Fujita
IPC分类号： C07D473/18 , C07D473/16 , A61K31/522 , A61P11/06 , A61P37/08
CPC分类号： A61K31/5377 , A61K31/522 , A61K31/55
摘要： A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene, etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents —COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.
摘要翻译：用作局部给药的药物，其作为抗过敏剂有效。用于局部给药的药物含有作为活性成分的由通式（1）表示的腺嘌呤化合物：[其中环A表示6至10元，单或双环，芳族烃或5至10元，单或双环，含有1至3个选自0至2个氮原子，0或1个氧原子和0或1个硫原子的杂原子的芳族杂环; n为0〜2的整数， m为0〜2的整数; R代表卤代，（取代）烷基等; X1代表氧，硫，NR1（R1代表氢或烷基）或单键; Y1表示单键，亚烷基等; Y2表示单键，亚烷基等; Z表示亚烷基; 并且Q1和Q2中的至少一个表示-COOR 10（其中R 10表示（un）取代的烷基等）等）或该化合物的药学上可接受的盐。

4. 发明授权

US5877318A Hydroquinone derivative and pharmaceutical use thereof 失效
标题翻译：对苯二酚衍生物及其药物用途
公开(公告)号：US5877318A
公开(公告)日：1999-03-02
申请号：US113826
申请日：1998-07-10
申请人： Yoshiaki Isobe , Yuso Goto , Masanori Tobe , Osamu Takahashi
发明人： Yoshiaki Isobe , Yuso Goto , Masanori Tobe , Osamu Takahashi
IPC分类号： C07D239/54 , C07D239/545 , C07D405/12
CPC分类号： C07D239/545 , C07D405/12
摘要： Disclosed is a hydroquinone derivative or a pharmaceutically acceptable salt thereof, the hydroquinone derivative being represented by formula (I): ##STR1## wherein R.sup.1 is a phenyl group which is unsubstituted or substituted with a substituent or substituents each independently selected from the group consisting of a halogen atom, a C1-4 alkyl group and a C1-4 alkoxy group;R.sup.2 is a hydrogen atom or a C1-4 alkyl group;each of R.sup.3 and R.sup.4 is independently a hydrogen atom or a C1-4 alkyl group;R.sup.5 is a hydrogen atom or a C1-4 alkyl group;each of R.sup.6, R.sup.7 and R.sup.8 is independently a hydrogen atom or a C1-4 alkyl group;P is a hydroxyl group;Q is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group;P may form together with Q an ether bond;R is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group, provided that when one of said Q and said R is an oxo group, the other is also an oxo group;X is a single bond, an --NR.sup.10 -- group or a --CH.sub.2 --NR.sup.10 -- group in which R.sup.10 is a hydrogen atom or a C1-4 alkyl group;Y is a methylene group or a carbonyl group; anddotted bonds in a six membered ring represent that said six membered ring has the maximum number of double bonds.
摘要翻译：公开了氢醌衍生物或其药学上可接受的盐，氢醌衍生物由式（I）表示：未取代或被各自独立地选自卤素原子，C 1-4烷基的取代基或取代基取代和C 1-4烷氧基; R2是氢原子或C1-4烷基; R 3和R 4各自独立地为氢原子或C 1-4烷基; R5是氢原子或C1-4烷基; R6，R7和R8各自独立地为氢原子或C1-4烷基; P是羟基; Q是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基; P可与Q形成醚键; R是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基，条件是当所述Q和所述R中的一个是氧代基时，另一个也是氧代基; X是单键，-NR 10 - 基或-CH 2 -NR 10 - 基，其中R 10是氢原子或C 1-4烷基; Y是亚甲基或羰基; 六元环中的点状键表示所述六元环具有最大数量的双键。

5. 发明授权

US06376501B1 Type 2 helper T cell-selective immune response suppressors 失效
标题翻译： 2型辅助性T细胞选择性免疫应答抑制剂
公开(公告)号：US06376501B1
公开(公告)日：2002-04-23
申请号：US09582176
申请日：2000-06-21
申请人： Yoshiaki Isobe , Haruhisa Ogita , Masanori Tobe , Haruo Takaku , Hiroyuki Matsui , Hideyuki Tomizawa
发明人： Yoshiaki Isobe , Haruhisa Ogita , Masanori Tobe , Haruo Takaku , Hiroyuki Matsui , Hideyuki Tomizawa
IPC分类号： A61K3152
CPC分类号： A61K31/522 , A61K31/52 , C07D473/00 , C07D473/34
摘要： The present invention relates to a type 2 helper T cell-selective immune response inhibitor, an immune response regulator and an anti-allergic agent, individually comprising, as an active ingredient, a purine derivative represented by General Formula (I): wherein R2 is hydrogen or a hydrocarbon group in which —CH2— not directly bound to the purine skeleton may be substituted by CO, SO2, O or S, and C—H not directly bound to the purine skeleton may be substituted by N, C-halogen or C—CN; R6 is hydroxyl, amino or amino which is mono- or di-substituted by a hydrocarbon group(s); R8 is hydroxyl, mercapto, acyloxy or hydrocarbon group-substituting oxycarbonyloxy; and R9 is a hydrocarbon group in which —CH2— not directly bound to the purine skeleton may be substituted by CO, SO2, O or S, and C—H not directly bound to the purine skeleton may be substituted by N, C-halogen or C—CN; or its tautomer or a salt of the purine derivative or the tautomer.
摘要翻译：本发明涉及一种2型辅助性T细胞选择性免疫应答抑制剂，免疫应答调节剂和抗过敏剂，其各自包含作为活性成分的由通式（I）表示的嘌呤衍生物：其中R 2为氢或其中不直接结合嘌呤骨架的-CH 2可以被CO，SO 2，O或S取代的烃基，并且不直接键合到嘌呤骨架上的CH可以被N，C-卤素或C-CN R6是羟基，被一个或多个烃基单取代或二取代的氨基或氨基; R8是羟基，巯基，酰氧基或烃基取代的氧羰基氧基; 并且R 9是其中不直接结合嘌呤骨架的-CH 2可以被CO，SO 2，O或S取代的烃基，并且不直接键合到嘌呤骨架上的CH可以被N，C-卤素或C- CN;或其互变异构体或嘌呤衍生物或互变异构体的盐。

6. 发明授权

US5821247A Hydroquinone derivative and pharmaceutical use thereof 失效
标题翻译：对苯二酚衍生物及其药物用途
公开(公告)号：US5821247A
公开(公告)日：1998-10-13
申请号：US933208
申请日：1997-09-16
申请人： Yoshiaki Isobe , Yuso Goto , Masanori Tobe , Osamu Takahashi
发明人： Yoshiaki Isobe , Yuso Goto , Masanori Tobe , Osamu Takahashi
IPC分类号： C07D239/54 , C07D239/545 , C07D405/12 , A61K31/51
CPC分类号： C07D239/545 , C07D405/12
摘要： Disclosed is a hydroquinone derivative or a pharmaceutically acceptable salt thereof, the hydroquinone derivative being represented by formula (I): ##STR1## wherein R.sup.1 is a phenyl group which is unsubstituted or substituted with a substituent or substituents each independently selected from the group consisting of a halogen atom, a C1-4 alkyl group and a C1-4 alkoxy group; R.sup.2 is a hydrogen atom or a C1-4 alkyl group; each of R.sup.3 and R.sup.4 is independently a hydrogen atom or a C1-4 alkyl group; R.sup.5 is a hydrogen atom or a C1-4 alkyl group; each of R.sup.6, R.sup.7 and R.sup.8 is independently a hydrogen atom or a C1-4 alkyl group; P is a hydroxyl group; Q is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group; P may form together with Q an ether bond; R is a hydroxyl group, a C1-4 alkoxy group, a C1-18 acyloxy group or an oxo group, provided that when one of said Q and said R is an oxo group, the other is also an oxo group; X is a single bond, an --NR.sup.10 --group or a --CH.sub.2 --NR.sup.10 --group in which R.sup.10 is a hydrogen atom or a C1-4 alkyl group; Y is a methylene group or a carbonyl group; and dotted bonds in a six membered ring represent that said six membered ring has the maximum number of double bonds.
摘要翻译：公开了氢醌衍生物或其药学上可接受的盐，所述对苯二酚衍生物由式（I）表示：未取代的或被各自独立地选自卤素原子，C 1-4烷基的取代基或取代基取代和C 1-4烷氧基; R2是氢原子或C1-4烷基; R 3和R 4各自独立地为氢原子或C 1-4烷基; R5是氢原子或C1-4烷基; R6，R7和R8各自独立地为氢原子或C1-4烷基; P是羟基; Q是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基; P可与Q形成醚键; R是羟基，C 1-4烷氧基，C 1-18酰氧基或氧代基，条件是当所述Q和所述R中的一个是氧代基时，另一个也是氧代基; X是单键，-NR 10 - 基或-CH 2 -NR 10 - 基，其中R 10是氢原子或C 1-4烷基; Y是亚甲基或羰基; 六元环中的点状键表示所述六元环具有最大数量的双键。

7. 发明申请

US20120178743A1 NOVEL ADENINE COMPOUND AND USE THEREOF 审中-公开
标题翻译：新颖的化合物及其用途
公开(公告)号：US20120178743A1
公开(公告)日：2012-07-12
申请号：US13402850
申请日：2012-02-22
申请人： Yoshiaki ISOBE , Haruo Takaku , Haruhisa Ogita , Masanori Tobe , Ayumu Kurimoto , Tetsuhiro Ogino , Hitoshi Fujita
发明人： Yoshiaki ISOBE , Haruo Takaku , Haruhisa Ogita , Masanori Tobe , Ayumu Kurimoto , Tetsuhiro Ogino , Hitoshi Fujita
IPC分类号： A61K31/52 , A61K31/5377 , A61P37/08 , A61P37/00 , A61P31/12 , A61P17/00 , C07D473/18 , A61K31/55
CPC分类号： A61K31/5377 , A61K31/522 , A61K31/55
摘要： An antiallergic agent for topical administration containing an adenine compound of general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene, etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents —COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.
摘要翻译：一种用于局部给药的抗过敏剂，其含有通式（1）的腺嘌呤化合物：[其中环A表示6至10元，单或双环，芳烃或5至10元单或双环芳族杂环，选自0至2个氮原子，0或1个氧原子和0或1个硫原子的3个杂原子; n为0〜2的整数， m为0〜2的整数; R代表卤代，（取代）烷基等; X1代表氧，硫，NR1（R1代表氢或烷基）或单键; Y1表示单键，亚烷基等; Y2表示单键，亚烷基等; Z表示亚烷基; 并且Q1和Q2中的至少一个表示-COOR 10（其中R 10表示（un）取代的烷基等）等）或该化合物的药学上可接受的盐。

8. 发明授权

US07157465B2 Adenine derivatives 失效
标题翻译：腺嘌呤衍生物
公开(公告)号：US07157465B2
公开(公告)日：2007-01-02
申请号：US10474199
申请日：2002-04-15
申请人： Yoshiaki Isobe , Haruhisa Ogita , Masanori Tobe , Haruo Takaku , Tetsuhiro Ogino , Ayumu Kurimoto , Hajime Kawakami
发明人： Yoshiaki Isobe , Haruhisa Ogita , Masanori Tobe , Haruo Takaku , Tetsuhiro Ogino , Ayumu Kurimoto , Hajime Kawakami
IPC分类号： C07D473/16 , C07D473/18 , C07D473/24 , A61K31/52 , A61K31/522
CPC分类号： C07D473/00 , C07D473/16 , C07D473/18 , C07D473/24 , C07D473/34
摘要： This invention relates to an adenine derivative, a tautomer thereof, or a pharmaceutically acceptable salt thereof represented by general formula (I): wherein X represents NR3 (wherein R3 represents a hydrogen atom or C1-3 alkyl) or the like; R1 represents substituted or unsubstituted alkyl or the like; R2 represents hydroxyl or the like; and Y represents a substituted or unsubstituted aromatic hetero ring or the like. Also, the present invention relates to pharmaceuticals such as an interferon inducer, antiviral agent, anticancer agent, type 2 helper T cell selective immune response inhibitor, antiallergic agent, and immune response modulator comprising the above derivative as an active ingredient.
摘要翻译：本发明涉及由通式（I）表示的腺嘌呤衍生物，其互变异构体或其药学上可接受的盐：其中X表示NR 3（其中R 3表示氢原子或C 1-3烷基）等; R 1表示取代或未取代的烷基等; R 2表示羟基等; Y表示取代或未取代的芳族杂环等。此外，本发明涉及包含上述衍生物作为活性成分的药物，例如干扰素诱导剂，抗病毒剂，抗癌剂，2型辅助T细胞选择性免疫应答抑制剂，抗过敏剂和免疫应答调节剂。

9. 发明申请

US20100256118A1 NOVEL ADENINE COMPOUND AND USE THEREOF 失效
标题翻译：新颖的化合物及其用途
公开(公告)号：US20100256118A1
公开(公告)日：2010-10-07
申请号：US12793649
申请日：2010-06-03
申请人： Yoshiaki ISOBE , Haruo Takaku , Haruhisa Ogita , Masanori Tobe , Ayumu Kurimoto , Tetsuhiro Ogino , Hitoshi Fujita
发明人： Yoshiaki ISOBE , Haruo Takaku , Haruhisa Ogita , Masanori Tobe , Ayumu Kurimoto , Tetsuhiro Ogino , Hitoshi Fujita
IPC分类号： A61K31/52 , C07D473/18 , A61K31/5377 , C07D473/24 , C07D473/16 , A61K31/55 , A61P11/06 , A61P17/00 , A61P37/02
CPC分类号： A61K31/5377 , A61K31/522 , A61K31/55
摘要： A drug for topically administration which is effective as an antiallergic agent. The drug for topically administration contains as an active ingredient an adenine compound represented by the general formula (1): [wherein ring A represents a 6 to 10 membered, mono or bicyclic, aromatic hydrocarbon or a 5 to 10 membered, mono or bicyclic, aromatic heterocycle containing one to three heteroatoms selected among 0 to 2 nitrogen atoms, 0 or 1 oxygen atom, and 0 or 1 sulfur atom; n is an integer of 0 to 2; m is an integer of 0 to 2; R represents halogeno, (un)substituted alkyl, etc.; X1 represents oxygen, sulfur, NR1 (R1 represents hydrogen or alkyl), or a single bond; Y1 represents a single bond, alkylene, etc.; Y2 represents a single bond, alkylene, etc.; Z represents alkylene; and at least one of Q1 and Q2 represents —COOR10 (wherein R10 represents (un)substituted alkyl, etc.), etc.] or a pharmaceutically acceptable salt of the compound.
摘要翻译：用作局部给药的药物，其作为抗过敏剂有效。用于局部给药的药物含有作为活性成分的由通式（1）表示的腺嘌呤化合物：[其中环A表示6至10元，单或双环，芳族烃或5至10元，单或双环，含有1至3个选自0至2个氮原子，0或1个氧原子和0或1个硫原子的杂原子的芳族杂环; n为0〜2的整数， m为0〜2的整数; R代表卤代，（取代）烷基等; X1代表氧，硫，NR1（R1代表氢或烷基）或单键; Y1表示单键，亚烷基等; Y2表示单键，亚烷基等; Z表示亚烷基; 并且Q1和Q2中的至少一个表示-COOR 10（其中R 10表示（un）取代的烷基等）等）或该化合物的药学上可接受的盐。

10. 发明授权

US07521454B2 Adenine derivatives 失效
标题翻译：腺嘌呤衍生物
公开(公告)号：US07521454B2
公开(公告)日：2009-04-21
申请号：US11582452
申请日：2006-10-18
申请人： Yoshiaki Isobe , Haruhisa Ogita , Masanori Tobe , Haruo Takaku , Tetsuhiro Ogino , Ayumu Kurimoto , Hajime Kawakami
发明人： Yoshiaki Isobe , Haruhisa Ogita , Masanori Tobe , Haruo Takaku , Tetsuhiro Ogino , Ayumu Kurimoto , Hajime Kawakami
IPC分类号： A61P11/06 , A61P17/00 , A61P35/00 , C07D473/16 , C07D473/18 , C07D473/24 , A61K31/52 , A61K31/522
CPC分类号： C07D473/00 , C07D473/16 , C07D473/18 , C07D473/24 , C07D473/34
摘要： This invention relates to an adenine derivative, a tautomer thereof, or a pharmaceutically acceptable salt thereof represented by general formula (I): wherein X represents NR3 (wherein R3 represents a hydrogen atom or C1-3 alkyl) or the like; R1 represents substituted or unsubstituted alkyl or the like; R2 represents hydroxyl or the like; and Y represents a substituted or unsubstituted aromatic hetero ring or the like. Also, the present invention relates to pharmaceuticals such as an interferon inducer, antiviral agent, anticancer agent, type 2 helper T cell selective immune response inhibitor, antiallergic agent, and immune response modulator comprising the above derivative as an active ingredient.
摘要翻译：本发明涉及由通式（I）表示的腺嘌呤衍生物，其互变异构体或其药学上可接受的盐：其中X表示NR 3（其中R 3表示氢原子或C 1-3烷基）等; R 1表示取代或未取代的烷基等; R2表示羟基等; Y表示取代或未取代的芳族杂环等。此外，本发明涉及包含上述衍生物作为活性成分的药物，例如干扰素诱导剂，抗病毒剂，抗癌剂，2型辅助T细胞选择性免疫应答抑制剂，抗过敏剂和免疫应答调节剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式